AUSTIN--(BUSINESS WIRE)--Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules (biomimetic therapeutics), today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately. Dr. Rudnic brings more than 30 years of diverse experience in the biosciences industry.
"We are pleased to welcome Ed to Maxwell Biosciences,” said Maxwell CEO and Co-Founder, Joshua McClure. "As an industry veteran with extensive biotech success under his belt, we are confident that Ed will bring valuable insights, proven leadership, new patents and new chemical entities to accelerate Maxwell’s breakthrough medicines to patients.”
Dr. Rudnic was the founder, chairman, and CEO of MiddleBrook Pharmaceuticals, where he raised $300M in financing and successfully brought the company public on the NASDAQ. Previously, he was the head of research and development in the U.S. at Shire Pharmaceuticals where he invented or co-invented three drug products, eventually earning the company $2 billion in annual sales. In addition, he previously held executive and leadership positions at Vivreon Biosciences, QRx Pharma, UnionBridge Management, Merck and Bristol-Myers Squibb.
“In more than 30 years in drug discovery, I’ve never seen a drug platform with the potential to benefit so many lives,” says Dr. Rudnic. “With such a diverse potential for indications – from virucidal, fungicidal, and bactericidal applications, to combating cancer – all under one technology platform, Maxwell’s CLAROMER platform is unmatched. It’s a privilege to join this team of talented innovators and to join their efforts to develop novel therapies to address the unmet needs of patients globally.”
Dr. Rudnic is either the lead inventor or a co-inventor of 56 issued U.S. patents and numerous related international patents. Several of his invented compounds have achieved $1 billion in revenue or greater. He is one of the most successful drug discovery executives in the industry. He holds a Bachelor of Science in Pharmacy, a Master of Science in Pharmaceutics and a Doctorate in Pharmaceutics, all from the University of Rhode Island.
About Maxwell
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics – synthetic compounds that mimic and improve upon biomolecules. Inspired by nature, these low-molecular weight compounds are created by Maxwell’s exclusive first-in-class, CLAROMER™ brand drug platform and have been shown to be effective in destroying viruses, bacteria, fungi and some cancers, while safely avoiding healthy cells. These drug candidates have been shown to be well-tolerated in human tissues in vitro, and in animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on Twitter and LinkedIn.
